BioSpace News Archive

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that it has received an additional 510(k) clearance by the FDA for Tactoset® Injectable Bone Substitute.

Scopus BioPharma Inc. today announced the appointments of John Rossi, Ph.D. and Nagy Habib, Ch.M., F.R.C.S. to the Scientific Advisory Board of Duet Therapeutics.

Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that management will present at the Cantor Global Healthcare Conference on Thursday, September 30, 2021 at 1:20 pm ET.

Blue Note Therapeutics, a prescription digital therapeutics company singularly dedicated to serving patients experiencing cancer, today announced a new collaboration with Memorial Sloan Kettering Cancer Center (MSK) to help advance the development of the company’s prescription digital therapeutic (PDT) candidate to treat fear of cancer recurrence.

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), announced today that members of its senior management team will participate in the SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines 1×1 Event, on September 23, 2021.

Kronos Bio, Inc., a company dedicated to transforming the lives of those affected by cancer, announced the appointment of Marni Kottle as senior vice president of Corporate Communications and Investor Relations.

Centene Corporation issued a reminder that it will release its 2021 third quarter financial results at approximately 6 a.m. on Tuesday, October 26, 2021, and host a conference call afterwards at approximately 8:30 a.m. to review the results.

Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today the signing of a multi-target drug discovery agreement with PhoreMost.

KSQ Therapeutics today announced the initiation of dosing in a Phase 1 clinical study of KSQ-4279, a first-in-class USP1 inhibitor, in patients with advanced solid tumors.

Appoints Tim Largen as VP of Manufacturing to drive cell therapy production strategy and direct collaborations with leading CDMOs